Glyconics Appoints Jeremy Williams as Non-Executive Director

Swansea, 24 February 2015 … Glyconics Limited has appointed Jeremy Williams as non-executive director, joining the Board of Directors. Glyconics, an innovative UK diagnostics company, is a spinout from Swansea University and is developing a novel diagnostic technology for the management of Chronic Obstructive Pulmonary Disease (COPD).

Jeremy joins the fast-growing company as it gears up for full commercialisation of its first product having secured a Small Business Research Initiative (SBRI) contract from NHS England to assess the clinical performance of the technology.

Jeremy brings considerable experience to the Board having been an entrepreneur and medical communications professional for many years. He is currently non-executive Chairman of Assembly Studios, in London and Abu Dhabi, Associate Director at SI Partners Global, a London-based firm offering management consultancy and corporate finance advice across Europe, Asia and North America. Jeremy is also founder of Stratus Communications Ltd, helping businesses to improve their performance, to manage rapid growth and to develop an exit strategy.

Prior to this, Jeremy was CEO and owner of ScopeMedical Ltd, a medical communications provider with clients from the global pharmaceutical industry, creating and implementing global healthcare communication programs. The company was the fastest growing firm in its sector had offices in the UK and US. Having led an MBO and subsequent business turnaround, Jeremy steered the company to seven fold growth over the next seven years. When he took the businesses to market they were acquired by Huntsworth Plc in an £11m acquisition in 2010.

Dr Berwyn Clarke, CEO of Glyconics, said: "Jeremy joins Glyconics at an exciting time in the Company's development as we build the Board and corporate infrastructure which will support the rapid progression of the technology. Jeremy brings great experience from the fields of medical education and medical communications, which will be valuable to Glyconics. Not only that, but he is an experienced non-executive director and we look forward to working closely with him at this exciting stage of the Company's development."

Jeremy Williams, non-executive director of Glyconics, added: "I am delighted to join the board of Glyconics. The company has an excellent technology, which meets a significant unmet clinical need, and I believe that this will be a highly significant commercial opportunity."

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.